• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    3 Reasons ArriVent BioPharma (AVBP) Looks Fairly Valued Following The FURVENT Setback

    Simply Wall St·10/08/2026 12:38:34
    语音播报

    Why the FURVENT setback matters for ArriVent BioPharma

    ArriVent BioPharma (AVBP) is under the microscope after reporting that its FURVENT Phase 3 trial of firmonertinib in EGFR exon 20 insertion NSCLC did not meet the primary progression free survival endpoint by independent review.

    The same study showed signs of clinical benefit on several secondary measures, including progression free survival assessed by investigators, a confirmed response rate at higher dosing, and a safety profile that compared favorably with platinum based chemotherapy.

    Investors are now weighing those mixed findings in light of a sharp share price reaction, ongoing legal investigations into past disclosures, and the role firmonertinib plays in ArriVent BioPharma’s broader oncology pipeline.

    For ArriVent BioPharma, the FURVENT update landed on top of a steep reset in expectations, with the stock recording a 7 day share price return of down 44.22% and a 30 day move of down 45.43%, although a 1 day gain of 11.93% from a US$16.89 share price hints at bargain hunting after that selloff, while the 1 year total shareholder return of down 18.88% reflects how pressure has built over a longer window rather than just this week.

    Scan beyond ArriVent BioPharma and stress test your thesis against 31 resilient stocks with low risk scores that have held up better on fundamentals and risk scores.

    ArriVent BioPharma now looks like a clinical story that just had its risk case repriced in a hurry. The real test is whether that reset already captures the hit to firmonertinib and the wider pipeline.

    Preferred Price-to-Book of 2.3x for ArriVent BioPharma: Is it justified?

    Valuation on ArriVent BioPharma now hinges on a simple question: Is a P/B of 2.3x a fair trade off for a pre revenue biotech with a key Phase 3 setback in the rearview mirror?

    The price to book multiple compares the market value of the equity to the accounting value of net assets. For a research heavy drug developer like ArriVent BioPharma that currently reports $0 in revenue and a net loss of $164.21m, the ratio is less about current earnings power and more about what investors are willing to pay for the cash, partnerships and pipeline on the balance sheet.

    On its own, a 2.3x P/B does not look extreme for a clinical stage biotech. The pressure point is that ArriVent BioPharma is still unprofitable, losses have increased over the past 5 years, returns on equity are negative at 44.76%, and analysts do not currently forecast profitability over the next 3 years. That mix suggests the market is paying more than book value while shouldering execution and funding risk, which raises the bar for how effectively future trial data and business development need to support the story.

    Set against the US Biotechs industry average P/B of 2x, ArriVent BioPharma trades at a premium. At the same time, the multiple screens as low compared with a peer group average of 34.3x, which shows how wide the valuation range can be for this corner of healthcare when sentiment swings toward or away from particular clinical assets.

    Result: Price-to-book of 2.3x (ABOUT RIGHT).

    See what the numbers say about this price — find out in our valuation breakdown.

    Still, the story around ArriVent BioPharma can change quickly if funding needs rise faster than expected or if additional firmonertinib data underwhelms regulators and partners.

    Find out about the key risks to this ArriVent BioPharma narrative.

    Next Steps

    Mixed messages around ArriVent BioPharma can easily influence your view in one direction. Respond promptly by stress testing both sides of the story with the 1 key reward and 4 important warning signs

    Looking for more investment ideas beyond ArriVent BioPharma?

    Do not stop with ArriVent BioPharma. Broaden your watchlist now, because the most interesting opportunities rarely wait around for investors to catch up.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.